File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Pure red cell aplasia: Clinical features and treatment results in 16 cases

TitlePure red cell aplasia: Clinical features and treatment results in 16 cases
Authors
KeywordsCyclosporine
Pure red cell aplasia
Steroids
Treatment
Issue Date1996
PublisherSpringer Verlag. The Journal's web site is located at http://link.springer.de/link/service/journals/00277/index.htm
Citation
Annals Of Hematology, 1996, v. 72 n. 3, p. 137-140 How to Cite?
AbstractPure red cell aplasia (PRCA) is a rare hematological disease characterized by selective marrow erythroid aplasia. We report the clinical features and treatment results of 16 Chinese patients with PRCA. Nine (56%) cases were not associated with any underlying disorders and were considered idiopathic, while seven patients (44%) had associated diseases, three involving the thymus, two with T large granular lymphocyte leukemia (T-LGLL), and one each with Stevens-Johnson syndrome and acute hepatitis A. Conventional-dose corticosteroid therapy resulted in complete remission in three of 13 patients. Cyclosporin A was used in six patients. There were three complete and one partial remissions. High-dose methylprednisolone was ineffective in four patients who failed conventional-dose corticosteroids but achieved complete remission in one patient with thymoma who did not respond to thymectomy. Antithymocyte globulin was used in four patients, resulting in partial remission in only one patient with concomitant T-LGLL. Intravenous gamma globulin and danazol were ineffective in three patients. Thymectomy was performed in two patients, with one patient remitting. This is the largest series of PRCA reported in an oriental population. Our results indicate that treatment of PRCA may still be problematic and better therapeutic strategy will have to be defined.
Persistent Identifierhttp://hdl.handle.net/10722/148056
ISSN
2023 Impact Factor: 3.0
2023 SCImago Journal Rankings: 0.912
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorKwong, YLen_HK
dc.contributor.authorWong, KFen_HK
dc.contributor.authorLiang, RHSen_HK
dc.contributor.authorChu, YCen_HK
dc.contributor.authorChan, LCen_HK
dc.contributor.authorChan, TKen_HK
dc.date.accessioned2012-05-29T06:10:36Z-
dc.date.available2012-05-29T06:10:36Z-
dc.date.issued1996en_HK
dc.identifier.citationAnnals Of Hematology, 1996, v. 72 n. 3, p. 137-140en_HK
dc.identifier.issn0939-5555en_HK
dc.identifier.urihttp://hdl.handle.net/10722/148056-
dc.description.abstractPure red cell aplasia (PRCA) is a rare hematological disease characterized by selective marrow erythroid aplasia. We report the clinical features and treatment results of 16 Chinese patients with PRCA. Nine (56%) cases were not associated with any underlying disorders and were considered idiopathic, while seven patients (44%) had associated diseases, three involving the thymus, two with T large granular lymphocyte leukemia (T-LGLL), and one each with Stevens-Johnson syndrome and acute hepatitis A. Conventional-dose corticosteroid therapy resulted in complete remission in three of 13 patients. Cyclosporin A was used in six patients. There were three complete and one partial remissions. High-dose methylprednisolone was ineffective in four patients who failed conventional-dose corticosteroids but achieved complete remission in one patient with thymoma who did not respond to thymectomy. Antithymocyte globulin was used in four patients, resulting in partial remission in only one patient with concomitant T-LGLL. Intravenous gamma globulin and danazol were ineffective in three patients. Thymectomy was performed in two patients, with one patient remitting. This is the largest series of PRCA reported in an oriental population. Our results indicate that treatment of PRCA may still be problematic and better therapeutic strategy will have to be defined.en_HK
dc.languageengen_US
dc.publisherSpringer Verlag. The Journal's web site is located at http://link.springer.de/link/service/journals/00277/index.htmen_HK
dc.relation.ispartofAnnals of Hematologyen_HK
dc.subjectCyclosporineen_HK
dc.subjectPure red cell aplasiaen_HK
dc.subjectSteroidsen_HK
dc.subjectTreatmenten_HK
dc.subject.meshAdrenal Cortex Hormones - Therapeutic Useen_US
dc.subject.meshAdulten_US
dc.subject.meshAgeden_US
dc.subject.meshAntilymphocyte Serum - Therapeutic Useen_US
dc.subject.meshBlood Transfusionen_US
dc.subject.meshCyclosporine - Therapeutic Useen_US
dc.subject.meshFemaleen_US
dc.subject.meshHumansen_US
dc.subject.meshMaleen_US
dc.subject.meshMethylprednisolone - Therapeutic Useen_US
dc.subject.meshMiddle Ageden_US
dc.subject.meshRed-Cell Aplasia, Pure - Physiopathology - Therapyen_US
dc.subject.meshRemission Inductionen_US
dc.subject.meshThymectomyen_US
dc.titlePure red cell aplasia: Clinical features and treatment results in 16 casesen_HK
dc.typeArticleen_HK
dc.identifier.emailKwong, YL:ylkwong@hku.hken_HK
dc.identifier.emailLiang, RHS:rliang@hku.hken_HK
dc.identifier.emailChan, LC:chanlc@hkucc.hku.hken_HK
dc.identifier.authorityKwong, YL=rp00358en_HK
dc.identifier.authorityLiang, RHS=rp00345en_HK
dc.identifier.authorityChan, LC=rp00373en_HK
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.doi10.1007/s002770050151en_HK
dc.identifier.pmid8766255-
dc.identifier.scopuseid_2-s2.0-0029869538en_HK
dc.identifier.hkuros13459-
dc.identifier.hkuros22799-
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-0029869538&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume72en_HK
dc.identifier.issue3en_HK
dc.identifier.spage137en_HK
dc.identifier.epage140en_HK
dc.identifier.isiWOS:A1996UD64200005-
dc.publisher.placeGermanyen_HK
dc.identifier.scopusauthoridKwong, YL=7102818954en_HK
dc.identifier.scopusauthoridWong, KF=7404759860en_HK
dc.identifier.scopusauthoridLiang, RHS=26643224900en_HK
dc.identifier.scopusauthoridChu, YC=55209144200en_HK
dc.identifier.scopusauthoridChan, LC=7403540707en_HK
dc.identifier.scopusauthoridChan, TK=7402687762en_HK
dc.identifier.issnl0939-5555-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats